Latest / Bloomberg Intelligence
GW's Gover on Cannabis-Derived Drug for Rare Epilepsy (Audio)
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Justin Gover, CEO of GW Pharmaceuticals, on the drug pipeline for the UK- based company which has been developing drug treatments derived from cannabis for decades.
See omnystudio.com/listener for privacy information.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.